Open Innovation

Open Innovation Portal

DNDi’s mission is to develop safe, effective, and affordable new treatments for patients suffering from neglected diseases and to ensure equitable access to these. Encouraging innovation is one way that we do this. Dedicated to fostering advancement in global health by supporting the research community in the field of neglected diseases, we have taken steps to disseminate the scientific knowledge gained through research projects with our many partners.This will be done through both the more traditional means of scientific publications, and less traditional means, notably by sharing data on chemical compounds in the public domain. 

In keeping with our Intellectual Property Policy, this portal offers updates of the data we post on two public databases: WIPO Re:Search and ChEMBL medicinal chemistry database.

The data we make available is the fruit of collaboration with our partners and is part of our constant effort to render accessible to entire scientific community, whenever possible:

• both positive and negative research results, as negative results can offer a wealth of information, allow for new research approaches to the same series with potentially different outcomes, and eliminate duplication of efforts

• data that DNDi and its partners have willfully agreed to place in the public domain, free of any and all  IP constraints.

                                                                      For more information, read "Striving for increasingly open innovation models" [PDF]


What’s new?

Screening identifies new compounds for HAT
Identification of compounds against Trypanosoma brucei brucei BS427 by high-throughput screening of whole parasites (87,926 compounds)

DNDi Screening of the MMV Open Access Malaria Box for HAT, VL, and Chagas disease 
Screening of the MMV Open Access Malaria Box in the search for new drugs against Human African Trypanosomiasis (HAT), visceral leishmaniasis and Chagas disease 


Previously...

 SCYNEXIS Inc. as part of the DNDi HAT Lead Optimization Consortium 
Screening and optimization of specific chemical series against human African Trypanosomiasis (HAT): 4926 compounds

 DNDi Lead Optimization Consortium (Epichem, Murdoch University, CDCO)
Optimization of fenarimol series for the treatment of Chagas disease: 751 compounds

For more information: partnership@dndi.org